Log In
Print this Print this

emicizumab (ACE910, RG6013, RO5534262)

  Manage Alerts
Collapse Summary General Information
Company Chugai Pharmaceutical Co. Ltd.
DescriptionBispecific mAb that binds Factor IXa and Factor X
Molecular Target Factor IXa
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationHemophilia
Indication DetailsTreat hemophilia A
Regulatory Designation U.S. - Breakthrough Therapy (Treat hemophilia A);
EU - Orphan Drug (Treat hemophilia A)
PartnerGenentech Inc.;

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today